New CEO backs Leo Pharma's transformation: "It is definitely the right strategy"

The new CEO of Leo Pharma is excited about the strategic direction at the company. This involves creating a more innovative portfolio, including eczema treatment tralokinumab, and she would like to accelerate the strategy further.

Photo: Leo Pharma, PR

It has been full-speed ahead when it comes to investments at Leo Pharma over the past few years, and that seems set to continue in 2020 and beyond.

The company’s new CEO, Catherine Mazzacco, is excited about the strategic direction, which aims to take the company away from resting on traditional dermatology products and towards establishing a portfolio of innovative treatments for eczema, psoriasis and other, rarer skin diseases.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs